iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
The filing is a Form 144 for iRhythm Technologies (IRTC) reporting a proposed sale of 5,312 common shares with an aggregate market value of $839,380.46. The shares are listed for sale on NASDAQ with an approximate sale date of 08/11/2025 and the issuer's total shares outstanding are reported as 32,127,763.
The filer states the shares were acquired on 08/11/2025 by stock option exercise from the issuer, with payment in cash, and the proposed sale will be executed through Morgan Stanley Smith Barney LLC. The form indicates nothing to report for securities sold by the filer in the past three months and includes the filer's representation that they do not know of undisclosed material adverse information about the issuer.
Form 144 filed for iRhythm Technologies (IRTC) shows an insider intends to sell a small block of common stock through Morgan Stanley Smith Barney on NASDAQ. The notice specifies 226 shares with an aggregate market value of $35,918.18, acquired under the company Employee Stock Purchase Plan on 11/30/2023 and paid for in cash. The filer previously sold 696 shares on 06/02/2025 for $97,586.16. With 32,127,763 shares outstanding reported on the form, the planned sale represents approximately 0.0007% of the outstanding shares, indicating the transaction is immaterial to total equity. The filer certifies there is no undisclosed material adverse information and includes standard Rule 10b5-1 language if applicable.
Form 144 summary: Form 144 notifies a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) on NASDAQ, approximate sale date 08/05/2025. Aggregate market value is reported as $4,816,190.87 and shares outstanding are reported as 32,127,763.
Acquisition history and disclosures: The form lists three acquisitions that total 30,000 shares—restricted stock 11/01/2023: 7,449; open-market purchase 06/06/2023: 9,755 (paid cash); restricted stock 11/01/2022: 12,796. The form states "Nothing to Report" for securities sold during the past three months. Several identification fields (filer CIK, issuer name, date of notice, signature) are blank in the provided content.